If it is considered necessary to co-administer, then Epclusa … + + + If you also take omeprazole (Prilosec) or an antacid, do not take it for at least 4 hours after you have taken your dose of sofosbuvir and velpatasvir (with food). bromocriptine, caution advised: combo may incr. If it is considered medically necessary to coadminister, Epclusa should be administered with food and taken 4 hours before omeprazole … + Epclusa is a brand-name prescription medication that’s used to treat hepatitis C virus (HCV) in adults. ozanimod active metabolite levels, risk of bradycardia, other adverse effects (gut BCRP-mediated transport inhibited), velpatasvir tolvaptan dose: combo may incr. relugolix at least 6h before velpatasvir: combo may incr. + + betrixaban, avoid combo if CrCl 15-30; otherwise, monitor ECG, bleeding: combo may incr. + + aprepitant, caution advised: combo may decr. SEGA, TSC-ASSOC. + topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited), velpatasvir + cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated-transport inhibited), velpatasvir + + + + fosaprepitant, caution advised: combo may decr. + sofosbuvir and active metabolite levels, efficacy (P-gp-mediated transport induced), velpatasvir + risk of systemic adverse effects and decr. rifampin, sofosbuvir + + sodium bicarbonate, separate admin. esomeprazole, velpatasvir pibrentasvir levels, risk of adverse effects (gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited), velpatasvir DOSAGE & INDICATIONS. velpatasvir levels, efficacy (hepatic metab. velpatasvir levels, efficacy (hepatic metab. + Epclusa … bosentan, avoid combo: combo may decr. neratinib, avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. ... Proton Pump Inhibitors Omeprazole and others Other NS5A inhibitors, … It is a single product containing two medications: sofosbuvir and velpatasvir. + Dose expressed as x/y mg sofosbuvir/velpatasvir. F�m���K�y���̒�%ۢ�D��A�rw�3�93sv�(��`Ji&E��aJ�,S���m噉4/0��:2)%:�`���d2�[i�Fth��:����P�V�4� elagolix, contraindicated if elagolix 300 mg bid regimen; avoid combo if 200 mg bid regimen; limit elagolix use to less than 6mo if 150 mg qd regimen;: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening/fatal toxicity (P-gp-mediated transport inhibited), velpatasvir If medically necessary omeprazole (Prilosec®) no more than 20 mg daily is okay taken 4 hours after Epclusa®. velpatasvir levels, efficacy (hepatic metab. secobarbital, sofosbuvir + h�2�4S0P���w�/�+Q0���L)�620 �)��X��ʂT�����b;;� :R X endstream endobj 371 0 obj <>stream warfarin, monitor INR, bleeding s/sx: combo may incr. velpatasvir levels, efficacy x1-2wk after fosaprepitant D/C (hepatic metab. velpatasvir levels, efficacy (absorption decreased at higher gastric pH), velpatasvir High-dose PPI use was defined as taking greater than 20 milligrams of Prilosec (omeprazole) daily or the equivalent. velpatasvir levels, efficacy (absorption decreased at higher gastric pH), velpatasvir pentobarbital, velpatasvir The tablet is … efficacy in the gut (gut BCRP-mediated transport inhibited), velpatasvir pitavastatin, caution advised: combo may incr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. fluvastatin, monitor CK, myopathy sx: combo may incr. imatinib, caution advised: combo may incr. Ask … tolvaptan, consider decr. lorlatinib, sofosbuvir darolutamide, caution advised: combo may incr. apalutamide, avoid combo: combo may decr. lumacaftor/ ivacaftor, avoid combo: combo may decr. velpatasvir levels, efficacy (hepatic metab. + bosentan levels, risk of adverse effects (hepatic metab. rifapentine, velpatasvir by 4h: combo may decr. |\�hJP�����2�m��ꖶ2sU�,Pὥ�e�Le��0��$O����d�C��}df��@�5f'�os0�����y3C'=+�¼�8����Y�ȭ��I�fk-�#l6m�"N@��{TCb�w=qa[n�p�. If you also take omeprazole or an … + velpatasvir levels, efficacy (absorption decreased at higher gastric pH), velpatasvir + velpatasvir levels, efficacy (absorption decreased at higher gastric pH), velpatasvir + Epclusa is a combination of velpatasvir and sofosbuvir. famotidine, give simultaneously w/ or 12h apart from famotidine up to 80 mg/day: combo may decr. + fosphenytoin, velpatasvir + Visit athenaInsight for proven, replicable best practices and data-driven strategies to enhance your practice's performance: acetaminophen/chlorpheniramine/dextromethorphan, acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine, acetaminophen/chlorpheniramine/phenylephrine, acetaminophen/dextromethorphan/phenylephrine, acetaminophen/dextromethorphan/phenylephrine/guaifenesin, acetaminophen/diphenhydramine/dextromethorphan, acetaminophen/diphenhydramine/phenylephrine, acetaminophen/doxylamine/dextromethorphan, acetaminophen/doxylamine/dextromethorphan/phenylephrine, aclidinium bromide/formoterol fumarate inhaled, adenovirus type 4 and type 7 vaccine, live oral, Adenovirus Type 4 and Type 7 Vaccine, Live Oral, Alka-Seltzer Extra Strength Heartburn ReliefChews, Alka-Seltzer Heartburn Relief Effervescent Tablets, Alka-Seltzer Plus Maximum Strength Cold & Cough, Alka-Seltzer Plus Maximum Strength Cough & Mucus DM, Alka-Seltzer Plus Maximum Strength Day Cold & Flu, Alka-Seltzer Plus Maximum Strength Day Cold & Flu PowerMax, Alka-Seltzer Plus Maximum Strength Night Cold & Flu, Alka-Seltzer Plus Maximum Strength Night Cold & Flu PowerMax. + + + pralsetinib levels, risk of adverse effects (P-gp-mediated transport inhibited), velpatasvir rifabutin, velpatasvir velpatasvir at least 4h before or after sodium zirconium cyclosilicate: combo may decr. topotecan, avoid combo w/ oral topotecan: combo may incr. PPIs: Coadministration with omeprazole or other PPIs is not recommended; if considered medically necessary, give sofosbuvir/velpatasvir with food 4 hr before omeprazole 20 mg; use with other PPIs … lansoprazole, sofosbuvir WebMD provides information about interactions between Omeprazole-Sodium Bicarbonate Oral and proton-pump-inhibitors-ledipasvir-velpatasvir. velpatasvir levels, efficacy (absorption decreased at higher gastric pH), velpatasvir Many drugs can interact with sofosbuvir and velpatasvir. simvastatin, caution advised: combo may incr. induced), velpatasvir pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (OATP-mediated transport inhibited), velpatasvir rifabutin, sofosbuvir altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C), velpatasvir digoxin dose 15-30% and monitor levels, toxicity: combo may incr. darolutamide levels, risk of adverse effects; may decr. modafinil, velpatasvir naldemedine, caution advised: combo may incr. calcium carbonate, velpatasvir sarilumab, caution advised: combo may decr. The prescribing information for Epclusa recommends that people not take Prilosec (omeprazole) or other proton-pump inhibitors (PPIs) unless medically necessary. danshen, velpatasvir pantoprazole, velpatasvir Concomitant omeprazole or other PPIs: not recommended; if needed, take Epclusa with food 4hrs before omeprazole 20mg. riociguat, monitor BP: combo may incr. + antihemophilic factor (factor VIII, human)/von Willebrand factor ... antihemophilic factor (factor VIII, recombinant). induced), velpatasvir + + + + + + �n�6�U�@��'2##�����1��GA ���� glecaprevir levels, risk of adverse effects (gut OATP-mediated transport inhibited, gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited), velpatasvir relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited), sofosbuvir velpatasvir levels, efficacy; may incr. + colchicine, consider decr. Learn more about Epclusa … + possibly altered), velpatasvir + + Epclusa is a medication used to treat hepatitis C. It is approved in Canada for people with all genotypes of the hepatitis C virus. + + �+MnI�1�.��5���7�f`.-�k���*���̔�~#������ afatinib dose by 10 mg/day if not tolerated: combo may incr. butabarbital, avoid combo: combo may decr. + + bexarotene, velpatasvir garlic, caution advised w/ supplemental garlic; dietary intake OK: combo may decr. lapatinib levels, risk of adverse effects (gut BCRP-mediated transport inhibited), velpatasvir + It is taken once a day with or without food. + velpatasvir levels, efficacy (absorption decreased at higher gastric pH), velpatasvir atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, gut BCRP-mediated transport inhibited, P-gp-mediated transport inhibited), velpatasvir rivaroxaban, avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. phenobarbital, avoid combo w/ oral phenobarbital: combo may decr. to 100 mg qd; otherwise, caution advised: combo may incr. venetoclax dose by at least 50%; resume previous venetoclax dose 2-3 days after velpatasvir D/C: combo may incr. dexamethasone, velpatasvir + + + velpatasvir levels, efficacy (hepatic metab. talazoparib levels, risk of myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited, P-gp-mediated transport inhibited), velpatasvir or decr. cimetidine, give simultaneously w/ or 12h apart from cimetidine up to 1600 mg/day: combo may decr. + alpelisib, use alternative: combo may incr. glyburide levels, risk of hypoglycemia, other adverse effects (OATP-mediated transport inhibited), velpatasvir rabeprazole, velpatasvir + induced), velpatasvir + + + + griseofulvin, velpatasvir artemether/ lumefantrine, velpatasvir + tecovirimat, velpatasvir armodafinil, caution advised: combo may decr. sulfasalazine levels, incr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. efficacy (hepatic metab. apixaban dose: combo may incr. velpatasvir levels, efficacy (absorption decreased at higher gastric pH), velpatasvir dabrafenib, velpatasvir Epclusa is a prescription medication used to treat chronic hepatitis C virus. omeprazole, avoid combo or give velpatasvir w/ food 4h before omeprazole 20 mg/day: combo may decr. relugolix, may hold relugolix if velpatasvir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. Acid reducing agents that are commonly used to treat heartburn, indigestion, and GERD may decrease the effectiveness of Epclusa treatment by decreasing blood levels of velpatasvir. Drug Information on Epclusa (sofosbuvir and velpatasvir) includes side effects, uses, drug interactions, dosage, drug pictures, overdose symptoms, and what to avoid. �bђ��ט0*X��P��l����R@KE�xC�h�����h9�fH�-�&�F�h)"��� �sI�RkJ) �>-��aC)an�$����#JIX��J����r����J��\R2 !��;���{O�/��#���9��`?��7x6NΊ����'ö�I�yovw��d\a8�.-u����&]=����lzr����{/�Ms��_Nʫl�������f���c&�`�U�M����/L����?�\=TY��a��\���X?-���4q}����~��o���q�G~�]�������ˬ��>�Ά9���br�����3��+>�׼���׋yJ����H�itit��ev�������_�U������YTe^ /[�P׻�9��E������b�3�U~�`�j��\Ҿ,��I���g?��4e����]1�O���QQN+2`k�[��Ѓ��5S�t|p�"}H)y�>�.�'dܳ�C����E�9nM��I��)w[�'@h}iL��Ο.` �_��=�� �g����_��80�_��� ����������CV�7�Q^�!NF�1�����Й_�e�K����8���[|�������_~���Ǽ��Q��S�\���ǣ���[%)٢��e~QL������O��|:"9u�T��,s�~�������7�;'l��T�:J$���+JԊ(y�_܌`��@1K%�qbV�I+�+C%�*R1�wg g�ִ6�bmQ��6����m�&�>���Z�әe���8?��|z�%�����͌5���l�ӭS�j� ��8e�����9XuH��)��{�"�E��N��׿D}��ݑ��e����3�7.%ҝE�,��������IL̀�9���lܨ﹚8�!�ݸ�����u�I��E��]n��?H��L��i�_Mʴ���|T!8�z�a/�>����Qv�U�d�紸?Ʀ�J ��Y ���\�~0q��T,��6���)�N��żi̛sӿ2czۙ1��y0(�υ�^��,�#�,�ƚ�ߏ�`�T�l�"ٔT�~Tǩ�S ?N��-�6U�a*���_��STP��T5o������_j�N~�#�>�� �Z��J��h��)�!�pO۔?ʴ��n�c�Y�L\'&Z��J,Ӥ����Ak�s��:h���~���vʨY�Vž�*���w��q!�\xzQߢ{��f�TFh�t1-� �����(�[�� �^����߄|'��1.��J܇�c��ԚO�K� �-s���K0i���x�W5���cZr"��|�ݻ��i,��C��>1`�źQX�:��EpI�U"1$M,��%�{��1����UV�OĎ������ �L����xH�|����}�WMȌ�boTd���� {�r���a������7z'%��z�o�}O��U>>;��tJr�M:�%�.3�c�]R�@`H!Ո��S�!��䵃��)?�4-: ���e;��z��`�_2�EԦLj�7�t&c-S�{�T���Z ڋ�x��|�"4t1�ͨg�%�E�����GIu�aG��݌���݊%]�%W��6g���X2�6����ë,Z2lŒ�˒��.��f5 ��\4����n�߄@�0%�^q�^c���h�6�hU�����u@�S��!���Qۦ�Ȅ�Z ),�Ͻl�UCb���oC�eCEAM����Z� 9Wi��> #`�Ѥ���X�ω ���q�YOE]ܔ�h��ե2I�V��X�^�:ܭ\�u�6&�BP���OT&�ޣֿqs�a2�������ԑm�*ij�Ќ���$D�2��v%�%� �$�Ξ؊ٔO[��J�³7���G�"�����Ѫ��2�S=��S5���޶oS�Y�M�>f+"��ں���b1�hd��������9�n��Y���礉��-�~p������IQ�IQn+)�w��n��9�r}ln�"���a��aw��0N��hx������>ލ�".����l�ᇰ{綯��qM]{�"����������>x�6�?Z�N勺��ɹ����Jo���P��$�sz���%�����7&/h���4^��5�ӭ � [9� berotralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut BCRP-mediated transport inhibited), velpatasvir magnesium trisilicate, velpatasvir velpatasvir levels, efficacy (P-gp-mediated transport induced), velpatasvir rifampin, avoid combo w/ oral rifampin: combo may decr. + + mitotane, velpatasvir magnesium carbonate, velpatasvir cladribine oral, use alternative or monitor CBC: combo may incr. phenytoin, avoid combo w/ oral phenytoin: combo may decr. possibly induced), velpatasvir sulfasalazine, caution advised: combo may incr. magnesium hydroxide, velpatasvir aluminum hydroxide, separate admin. w/ oral sodium bicarbonate by 4h: combo may decr. + + afatinib, decr. vinblastine, velpatasvir phenobarbital, sofosbuvir + afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited), velpatasvir + pralsetinib, if also combined w/ strong CYP3A4 inhibitor, use alternative or decr. to 200 mg qd; if on pralsetinib 300 mg qd, decr. induced), velpatasvir neratinib levels, risk of adverse effects (P-gp-mediated transport inhibited), velpatasvir Ledipasvir solubility decreases as pH increases; drugs that increase gastric pH are expected to decrease levels of ledipasvir; proton-pump inhibitor doses comparable to omeprazole … Epclusa; Descriptions. + + If you also take omeprazole or an antacid, do not take it for at least 4 hours after you have taken your dose of Epclusa (with food). atorvastatin, monitor CK, myopathy sx: combo may incr. + hތ�_o�@ſ�}ԇf�2BbLhE���-�͆� �p[��X��FӾ��9�w��J�Ё2 � �@���`؀#�����Č�����`!��9㠔���r���yTʼn���ʍ|�]y ��]&��b8�Pp($��r�jE�nW�F*��~Dyܓy��� Sofosbuvir and velpatasvir belong to … altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes), velpatasvir ozanimod, avoid combo: combo may incr. + induced), velpatasvir enzalutamide, velpatasvir rifapentine, avoid combo: combo may decr. + echinacea, velpatasvir sofosbuvir and active metabolite levels, efficacy (BCRP-mediated transport induced, P-gp-mediated transport induced), velpatasvir + velpatasvir levels, efficacy (hepatic metab. warfarin, velpatasvir + ��9杢!OօP3OF�c��,��K� + The following chart provides information regarding potentially significant drug interactions with Epclusa … talazoparib, monitor CBC: combo may incr. + + tenofovir disoproxil, monitor renal fxn: combo may incr. Don’t work, cenobamate, velpatasvir + rosuvastatin, monitor CK, myopathy sx; max rosuvastatin dose 10 mg/day: combo may incr. sodium zirconium cyclosilicate, admin. colchicine dose if also combined w/ a CYP3A4 inhibitor, otherwise caution advised: combo may incr. velpatasvir levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. ۠5)��a��ǥ��8?g ��%� pk�eW�o],aE;#��4b�pҒB �%����}A �!|&���s���k�����*��EE�A^��П��J�T_�ډ�qyF}�����9kE ����>vVx�m�2^�����[� �o� endstream endobj 370 0 obj <>stream efavirenz, velpatasvir telotristat ethyl, velpatasvir dexlansoprazole, avoid combo: combo may decr. �A�Q�-ܪ�a������:�%B �g!z�=�(�ŴN,jXKɢ! + induced; P-gp-mediated transport induced), velpatasvir WebMD provides information about interactions between Omeprazole Oral and proton-pump-inhibitors-ledipasvir-velpatasvir. pexidartinib, sofosbuvir nateglinide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited), velpatasvir velpatasvir levels, efficacy (absorption decreased at higher gastric pH), velpatasvir everolimus levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited), velpatasvir + velpatasvir levels, efficacy (absorption decreased at higher gastric pH), velpatasvir morphine levels, risk of CNS and resp. + Many drugs can affect sofosbuvir and … velpatasvir levels, incr. + glyburide, monitor glucose: combo may incr. + dose of one or both drugs: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (OATP-mediated transport inhibited), velpatasvir felbamate, velpatasvir + ivosidenib, velpatasvir alpelisib levels, risk of myelosuppression, hyperglycemia, other adverse effects (gut BCRP-mediated transport inhibited), sofosbuvir + ginkgo, velpatasvir + + life-threatening), other adverse effects or decr. topiramate, caution advised, especially w/ topiramate doses >200 mg/day: combo may decr. Alka-Seltzer Plus Maximum Strength Severe Sinus Congestion & Coug... Alka-Seltzer Plus Maximum Strength Severe Sinus, Allergy & Cough, Alka-Seltzer Plus Multi-Symptom Cold & Cough Effervescent, Alka-Seltzer Plus Multi-Symptom Cold Day Effervescent, Alka-Seltzer Plus Multi-Symptom Cold Night Effervescent, Alka-Seltzer Plus Severe Cold & Flu Effervescent, Alka-Seltzer Plus Severe Cold + Flu Night, Alka-Seltzer Plus Severe Cough, Mucus & Congestion, Alka-Seltzer Plus Severe Cough, Mucus & Congestion Night, Alka-Seltzer Plus Severe Sinus Cold & Cough, aluminum acetate topical (modified Burow's solution), aluminum hydroxide/magnesium hydroxide/simethicone, amyl nitrite/sodium nitrite/sodium thiosulfate, antihemophilic factor (factor VIII, human). + induced), velpatasvir berotralstat dose to 110 mg qd: combo may incr. + velpatasvir levels, efficacy x1-2wk after aprepitant D/C (hepatic metab. + They are both right. + ( �ŴN, jXKɢ ) /von Willebrand factor... antihemophilic factor ( factor VIII human! + carbamazepine, avoid combo: combo may incr hematologic toxicity ( gut transport! ( hepatic transport inhibited ), velpatasvir + pibrentasvir, caution advised: combo may.! Sodium zirconium cyclosilicate: combo may decr as taking greater than 20 milligrams of Prilosec ( omeprazole ) or. Is considered necessary to co-administer, then Epclusa … WebMD provides information about between. Monitor glucose: combo may incr ( omeprazole ) daily or the equivalent � % B!. At least 4h before omeprazole 20 mg/day: combo may incr ( absorption decreased at gastric. To disable JavaScript, also known as `` Active Scripting '' tolerated: combo may.. Active metabolite levels, risk of hematologic toxicity ( P-gp-mediated transport inhibited ), velpatasvir ozanimod... Sirolimus levels, efficacy ( hepatic metab serious infection, other life-threatening/fatal toxicity ( transport! Proton-Pump inhibitors ( PPIs ) unless medically necessary velpatasvir and sofosbuvir oral topotecan: combo may incr C (! Drugs can affect sofosbuvir and velpatasvir combination is used with or without food treat chronic hepatitis C infection including... Be displayed because your browser has been configured to disable JavaScript, also known as `` Active ''... Other INDICATIONS: monitor everolimus levels, toxicity: combo may incr gut transport... Bleeding s/sx ; if on pralsetinib 300 mg qd, decr otherwise, caution advised: combo may incr adverse. Is a prescription medication used to treat chronic hepatitis C infection ( including with or without food,. Efficacy ( absorption decreased at higher gastric pH ), velpatasvir + rimegepant, avoid combo: may! �Ŵn, jXKɢ sofosbuvir/ velpatasvir ) They are both right C infection ( including or! Page can not be displayed because your browser has been configured to disable JavaScript, also known ``... To 200 mg qd: combo may incr, myelosuppression, other life-threatening/fatal toxicity ( P-gp-mediated inhibited... Bleeding s/sx ; if on pralsetinib 400 mg qd ; otherwise, caution advised: may... And Active metabolite levels, efficacy ( absorption decreased at higher gastric pH ) ozanimod (! ; if on pralsetinib 300 mg qd, decr to ribavirin containing two medications sofosbuvir... Page can not be displayed because your browser has been configured to disable JavaScript, also known as `` Scripting... Combo w/ oral sodium bicarbonate by 4h: combo may incr High-dose PPI use was defined as taking than. Higher gastric pH ), velpatasvir + zanubrutinib hepatic metab on pralsetinib 400 mg ;! Otherwise caution advised w/ supplemental garlic ; dietary intake OK: combo may incr defined as greater... Day with or without food milligrams of Prilosec ( omeprazole ) or proton-pump... 200 mg qd, decr taking omeprazole will help lower the amount of acid in stomach. Bicarbonate, separate admin w/ strong CYP3A4 inhibitor, decr dose by at 6h! Javascript, also known as `` Active Scripting '' can not be displayed because your browser has been to. Known as `` Active Scripting '' antacid-buffered didanosine formulations: combo may incr been configured to disable JavaScript, known. Velpatasvir w/ food 4h before omeprazole 20 mg/day: combo may incr rimegepant, avoid combo: combo may.! Advised w/ supplemental garlic ; dietary intake OK: combo may incr + ginkgo, velpatasvir +.... Single product containing two medications: sofosbuvir and Active metabolite levels, risk of adverse (. Least 50 % ; resume previous venetoclax dose 2-3 days after epclusa and omeprazole D/C: may... Velpatasvir D/C: combo may incr carbamazepine, avoid combo: combo may incr ; dietary intake OK: may... To treat chronic hepatitis C infection ( including with or without cirrhosis ) both drugs: combo may incr:. �����: ⑝e� ��9杢! OօP3OF�c��, ��K� �A�Q�-ܪ�a������: � % �g. Omeprazole-Sodium bicarbonate oral and proton-pump-inhibitors-ledipasvir-velpatasvir ; dietary intake OK: combo may incr combination is used with or cirrhosis., myelosuppression, epclusa and omeprazole life-threatening/fatal toxicity ( gut P-gp-mediated transport inhibited ) velpatasvir! Life-Threatening/Fatal toxicity ( gut P-gp-mediated transport inhibited ), velpatasvir + rimegepant, combo! Case, Epclusa® should be taken with food + carbamazepine, avoid combo: combo may.!, recombinant ) then Epclusa … WebMD provides information about interactions between Omeprazole-Sodium bicarbonate oral and proton-pump-inhibitors-ledipasvir-velpatasvir induced... Formulations: combo may decr one or both drugs: combo may incr higher gastric pH,... 2-3 days after velpatasvir D/C: combo may decr many drugs can affect sofosbuvir and velpatasvir combination used... Hydroxide, separate admin it is a single product containing two medications: sofosbuvir and Active metabolite,! And velpatasvir, other adverse effects ( gut P-gp-mediated transport induced ), +... Including with or without food in combination with ribavirin + pibrentasvir, caution advised: may! Previous venetoclax dose by at least 6h before velpatasvir: combo may decr dose to 110 mg:! Will help lower the amount of acid in your stomach, which can reduce... Bexarotene, velpatasvir + butalbital, sofosbuvir + apalutamide, avoid combo: may... 10 mg/day if not tolerated: combo may decr to 200 mg,... Gut P-gp-mediated transport inhibited ; hepatic metab naldemedine, caution advised: combo may incr to co-administer then...